Beyond tumor control: skeletal morbidity in giant prolactinoma
Abstract
Multimodal management of giant prolactinoma with extensive amyloid spherule deposition: a case report with review of the literature' [1].The authors present a remarkable and highly informative case of giant prolactinoma with extensive amyloid spherule deposition, emphasizing dopamine agonist resistance, aggressive local behaviour, and the potential value of multimodal treatment.The detailed discussion of radiotherapy, temozolomide, and possible restoration of dopamine sensitivity provides an important clinical perspective on a rare and challenging entity [1].I would like to highlight another clinically relevant aspect of giant prolactinoma that may deserve greater attention, particularly in male patients: skeletal morbidity.In the present case, the patient had longstanding hypogonadal symptoms, documented hypogonadotropic hypogonadism, and later required testosterone replacement; however, bone health evaluation was not described [1].Given the established adverse effects of hyperprolactinemia and hypogonadism on bone metabolism, assessment of fracture history and bone mineral density may provide useful complementary clinical information in such patients [2].
Related
- Skeletal assessment in giant prolactinoma: a reply
- CT-Defined Low Skeletal Muscle Mass, Prognostic Nutritional Index, and Anemia in Relation to In-Hospital Major Morbidity After Gastrectomy for Gastric Carcinoma: A Retrospective Cohort Study
- Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma
- Impact of breastfeeding beyond 12 months on HIV transmission, mortality and morbidity among HIV-exposed uninfected infants in sub-Saharan Africa: a protocol for a systematic review and meta-analysis
- Craniopharyngioma Across the Lifespan: A Large Single-Center Cohort Study of Surgical Outcomes, Endocrine Morbidity, and Long-Term Disease Control
BibTeX
@article{dandinoglu2026beyond,
title = {{Beyond tumor control: skeletal morbidity in giant prolactinoma}},
author = {Taner Dandinoğlu},
journal = {Endocrine Journal},
year = {2026},
month = sep,
doi = {10.1507/endocrj.ej26-0353},
url = {https://www.jstage.jst.go.jp/article/endocrj/73/9/73_EJ26-0353/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Beyond tumor control: skeletal morbidity in giant prolactinoma
AU - Taner Dandinoğlu
PY - 2026
DA - 2026/09/01
JO - Endocrine Journal
DO - 10.1507/endocrj.ej26-0353
UR - https://www.jstage.jst.go.jp/article/endocrj/73/9/73_EJ26-0353/_article
AB - Multimodal management of giant prolactinoma with extensive amyloid spherule deposition: a case report with review of the literature' [1].The authors present a remarkable and highly informative case of giant prolactinoma with extensive amyloid spherule deposition, emphasizing dopamine agonist resistance, aggressive local behaviour, and the potential value of multimodal treatment.The detailed discussion of radiotherapy, temozolomide, and possible restoration of dopamine sensitivity provides an important clinical perspective on a rare and challenging entity [1].I would like to highlight another clinically relevant aspect of giant prolactinoma that may deserve greater attention, particularly in male patients: skeletal morbidity.In the present case, the patient had longstanding hypogonadal symptoms, documented hypogonadotropic hypogonadism, and later required testosterone replacement; however, bone health evaluation was not described [1].Given the established adverse effects of hyperprolactinemia and hypogonadism on bone metabolism, assessment of fracture history and bone mineral density may provide useful complementary clinical information in such patients [2].
SN - 1348-4540
SN - 0918-8959
ER -